Community Research and Development Information Service - CORDIS


SCIENCE Report Summary

Project ID: 643478
Funded under: H2020-EU.3.1.

Periodic Reporting for period 1 - SCIENCE (Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE))

Reporting period: 2015-01-01 to 2016-06-30

Summary of the context and overall objectives of the project

Ischemic heart disease (IHD) caused by coronary artery disease is the most common cause of death with more than 17 million deaths worldwide each year and a major cause of hospital admissions in industrialized countries. It is an increasing economic health problem due to increasing morbidity in an ageing population. Classical therapies have reduced mortality of IHD significantly, but left an increasing number of patients with chronic IHD and/or heart failure without further treatment options.

There is an unmet need for novel, effective treatments for chronic IHD and heart failure to improve patient’s survival and quality of life and reduce health care costs. Stem cell therapy is emerging as a viable therapeutic option in this patient group as well as in several debilitating diseases for which no cure is currently available.

The overall aim of the SCIENCE project is
• to conduct a multi-center double-blind placebo-controlled trial with stem cells from healthy donors to improve myocardial function in patients with ischemic heart disease and heart failure.
• establishing a manufacture facility for centralized production of the stem cell product in Copenhagen, Denmark.
• establishing financial health care data to demonstrate the impact of implementing stem cell treatment
• evaluating advanced existing and new imaging techniques of the function of the heart in order to establish future more precisely guided delivery of stem cells

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

Within the first 18 months grant period the consortium has established the centralized production of stem cells for the clinical trial in Copenhagen, Denmark.

The approval of the clinical project has been a little delayed due to new regulation for some of the component used in the stem cell production which was released late 2015 to be implemented 2017. The new regulation was released after our submission of the project to the competent authorities for an approval. We therefore had to establish a completely new production of stem cell for the clinical trial based on the upcoming new regulation and initiate a new approval process. This new production plan is now approved by the competent authorities in the involved countries and the new production of the stem cell product has been initiated. It is expected that the first patient will be treated medio September 2016.

We have established an organization for initiating and monitoring of the six involved clinical departments in Slovenia, Germany, Austria, Poland, The Netherlands and Denmark.

There has been developed guiding protocols describing all practical steps in the clinical trial from including patients, testing the capacity of the patients and their heart function, handling of and treatment with the stem cells etc. to optimize the patient treatment and minimize the risk in the study.

The plan and protocols for the imaging investigation of the patient’s heart function with Echocardiography, Computer Tomography and Magnetic Resonance Imaging are all developed and tested by the participating clinical partners,

We have developed a plan for the evaluation and impact of of the stem cell therapy on health economy.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Nothing in the present period.

Related information

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top